Saturday 17 October 2026 Export RIGL’s income statement to Excel — free account

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024. In the quarter to June 2026, revenue fell 22.6%, EPS fell 72.1%, free cash flow fell 230.0% and total debt fell 66.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

45.97 1.28 −2.71%

Follow RIGL

Alert me

Market cap: $882.6M
P/E: 2.6×
Fwd P/E: 7.9×
Dividend yield: —
F-score: 6/9
Altman Z: 2.70
Beneish M: 0.78
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.31

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	1	—	—	1	1	—	—	—	—

Insider Ownership 2.59%

Capital & Financial Ratios $m

Market Cap 882.62

Revenue 276.79

Net Income 321.91

Free Cash Flow 8.82

Net Debt (95.33)

Current Ratio 1.94

Debt/Equity 0.00

P/E ratio 2.60

Fwd P/E 7.93

P/S ratio 3.08

P/B ratio 2.00

Past 5Y EPS Growth —

This Y EPS Growth (82.39%)

Next Y EPS Growth 33.56%

Next Y revenue growth 3.88%

Next 5Y EPS Growth 67.79%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 42.43%

10-year low 10-year high

P/B against its own 10 years 8.30%

10-year low 10-year high

EV/Sales against its own 10 years 45.74%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	57	77	155	95
Receivables	31	42	52	56
Inventory	6	6	12	14
Other	—	—	—	—
	99	135	240	186

	2023	2024	2025	Q'26
Payables	7	3	7	4
ST’ Debt	—	—	—	—
Other	19	38	44	28
	53	63	99	96

Compound Annual Growth %

	10y	5y	3y
Sales	26.12%	22.06%	34.76%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	15.66%	63.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	59	79	—	—	—
’25	53	102	69	70	294
’24	30	37	55	58	179
’23	26	27	28	36	117
’22	17	30	22	51	120
’21	81	26	22	20	149
’20	56	16	18	18	109

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	31	—	—	—
’25	(1)	31	24	22	76
’24	(5)	0	22	15	31
’23	(4)	6	(1)	(6)	(6)
’22	(26)	(13)	(13)	(22)	(74)
’21	(20)	55	(10)	(19)	6
’20	(3)	(14)	(19)	(16)	(52)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	(40)	—	—	—
’25	(1)	31	24	22	76
’24	(5)	0	22	15	31
’23	(19)	6	(1)	(6)	(20)
’22	(26)	(13)	(13)	(22)	(73)
’21	(20)	55	(10)	(19)	5
’20	(4)	(14)	(20)	(16)	(53)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.44	0.88	—	—	—
’25	0.63	3.28	1.46	13.54	19.48
’24	(0.50)	(0.06)	0.70	0.80	0.99
’23	(0.80)	(0.40)	(0.30)	0.04	(1.40)
’22	(1.60)	(0.80)	(1.10)	0.10	(3.40)
’21	2.20	(0.80)	(1.20)	(1.30)	(1.10)
’20	1.30	(1.00)	(0.80)	(1.10)	(1.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	18.80	19.40	19.60	15.60	12.30	23.00	6.40	7.10	7.48	15.50	Analyst estimates 2026–2028 Powerpack
	High	43.80	44.70	47.10	26.90	52.40	55.00	35.20	20.40	29.82	52.24
People
People	Employees	77	103	158	163	169	165	155	147	164	174
	Revenue/emp, $m	0.26	0.04	0.28	0.36	0.64	0.90	0.78	0.80	1.09	1.69
Income, $m
Income, $m	Revenue	20	4	45	59	109	149	120	117	179	294
	Gross margin, %	100.00	100.00	99.36	98.47	99.18	99.27	98.55	93.92	89.60	93.33
	EBT	(69)	(78)	(70)	(67)	(30)	(17)	(59)	(25)	18	122
	EBT margin, %	(339.58)	(1,739.34)	(158.35)	(112.83)	(27.38)	(11.60)	(48.71)	(21.47)	10.24	41.40
	Net income	(69)	(78)	(70)	(67)	(30)	(18)	(59)	(25)	17	367
	Depreciation	1	0	0	0	1	1	1	1	2	1
Per share, $
Per share, $	Revenue	2.16	0.36	2.77	3.54	6.44	8.75	7.05	6.72	10.20	16.36
	Earnings	(7.30)	(6.20)	(4.40)	(4.00)	(1.80)	(1.10)	(3.40)	(1.40)	0.99	20.40
	Cash flow	(8.04)	(6.14)	(3.66)	(2.48)	(3.09)	0.34	(4.33)	(0.33)	1.79	4.21
	Capex	(0.08)	0.05	(0.07)	(0.09)	(0.07)	(0.04)	0.03	(0.85)	(0.02)	0.00
	Free cash flow	(8.12)	(6.09)	(3.73)	(2.57)	(3.17)	0.31	(4.30)	(1.18)	1.77	4.21
	Book value	5.83	7.97	6.84	3.21	2.02	1.78	(0.80)	(1.65)	0.19	21.76
	Shares, m	9	13	16	17	17	17	17	17	18	18
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	17.52	2.12
	P/S	11.53	44.49	8.13	6.04	5.44	3.03	1.90	2.17	1.65	2.62
	P/B	4.27	4.97	3.36	6.66	17.36	14.87	0.00	0.00	89.93	1.97
	EV/Sales	7.87	34.22	5.31	4.55	5.09	2.32	1.74	2.13	1.51	2.17
	EV/FCF	(2.10)	(5.00)	(4.02)	(6.28)	(10.35)	66.04	(2.86)	(12.18)	8.65	8.45
Cash, $m
Cash, $m	Operating cash flow	(76)	(78)	(59)	(42)	(52)	6	(74)	(6)	31	76
	Capex	(1)	1	(1)	(1)	(1)	(1)	0	(15)	0	—
	Free cash flow	(77)	(77)	(60)	(43)	(53)	5	(73)	(20)	31	76
Balance, $m
Balance, $m	Working capital	54	99	109	61	48	91	51	46	72	141
	Total debt	0	—	—	10	20	20	39	52	52	22
	Net debt	(75)	(116)	(129)	(88)	(38)	(105)	(19)	(5)	(25)	(132)
	Shareholders’ equity	55	101	110	54	34	30	(14)	(29)	3	391
Returns, %
Returns, %	ROA	(65.96)	(79.08)	(54.59)	(46.67)	(23.06)	(12.90)	(38.84)	(19.95)	12.44	108.34
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	30.28
	ROE	(94.55)	(100.20)	(66.96)	(81.73)	(67.72)	(55.63)	(699.05)	118.75	(137.92)	185.94

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CGEM Cullinan Therapeutics, Inc.	$901.0M	— (loss-making)	4.8×	—	n/m	+33.66% (above 0%: growing)	100.00%	0.00%	Compare
AKTS Aktis Oncology, Inc.	$890.5M	— (loss-making)	— (loss-making)	—	n/m	−12.77% (below 0%: shrinking)	100.00%	(853.99%)	Compare
ANRO Alto Neuroscience, Inc.	$887.7M	— (loss-making)	—	—	n/m	−43.41% (below 0%: shrinking)	—	0.00%	Compare
RIGL Rigel Pharmaceuticals, Inc.	$882.6M	2.6×	7.9×	−22.60% (below 0%: shrinking)	−72.07% (below 0%: shrinking)	−229.99% (below 0%: shrinking)	89.17%	29.95%
JBIO Jade Biosciences, Inc.	$875.1M	— (loss-making)	—	—	n/m	−115.11% (below 0%: shrinking)	0.00%	0.00%	Compare
MLTX MoonLake Immunotherapeutics	$873.2M	— (loss-making)	—	—	n/m	−1.89% (below 0%: shrinking)	0.00%	0.00%	Compare
GLUE Monte Rosa Therapeutics, Inc.	$863.4M	— (loss-making)	— (loss-making)	−61.33% (below 0%: shrinking)	n/m	−34.11% (below 0%: shrinking)	100.00%	(547.84%)	Compare
KURA Kura Oncology, Inc.	$862.9M	— (loss-making)	— (loss-making)	+36.54% (above 0%: growing)	n/m	−109.05% (below 0%: shrinking)	98.84%	(349.77%)	Compare
ALMS Alumis Inc.	$842.4M	— (loss-making)	— (loss-making)	−37.66% (below 0%: shrinking)	n/m	+23.59% (above 0%: growing)	100.00%	(8,956.38%)	Compare
Median of peers	$874.1M	—	—	−37.66%	—	−23.44%	100.00%	(174.88%)

All 614 Biotechnology stocks →

Rigel Pharmaceuticals, Inc. (RIGL) key facts

Strength: Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024.
Rigel Pharmaceuticals, Inc. (RIGL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RIGL traded at $45.97, a market capitalization of $882.6 million.
Return on equity was 185.9% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.70 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.